Nuria Gresa-Arribas1, Jesús Planagumà1, Mar Petit-Pedrol1, Izumi Kawachi1, Shinichi Katada1, Carol A Glaser1, Mateus M Simabukuro1, Thaís Armangué1, Eugenia Martínez-Hernández1, Francesc Graus1, Josep Dalmau2. 1. From the Neuroimmunology Program, Biomedical Research Institute August Pi i Sunyer (IDIBAPS) (N.G.-A., J.P., M.P.-P., T.A., E.M.-H., F.G., J.D.), and Service of Neurology, Hospital Clínic (F.G.), University of Barcelona, Spain; Department of Neurology (I.K., S.K.), Brain Research Institute, Niigata University, Japan; Division of Pediatric Infectious Diseases (C.A.G.), Kaiser Permanente, Oakland Medical Center and University of California, San Francisco; Neurology Division (M.M.S.), Hospital das Clínicas, São Paulo University (HC/FMUSP), Brazil; Pediatric Neuroimmunology Unit (T.A.), Sant Joan de Déu Children's Hospital; Department of Neurology (J.D.), University of Pennsylvania, Philadelphia; and Catalan Institution for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. N.G.-A. is currently affiliated with the Department of Neuroscience, Karolinska Institute, Stockholm, Sweden. 2. From the Neuroimmunology Program, Biomedical Research Institute August Pi i Sunyer (IDIBAPS) (N.G.-A., J.P., M.P.-P., T.A., E.M.-H., F.G., J.D.), and Service of Neurology, Hospital Clínic (F.G.), University of Barcelona, Spain; Department of Neurology (I.K., S.K.), Brain Research Institute, Niigata University, Japan; Division of Pediatric Infectious Diseases (C.A.G.), Kaiser Permanente, Oakland Medical Center and University of California, San Francisco; Neurology Division (M.M.S.), Hospital das Clínicas, São Paulo University (HC/FMUSP), Brazil; Pediatric Neuroimmunology Unit (T.A.), Sant Joan de Déu Children's Hospital; Department of Neurology (J.D.), University of Pennsylvania, Philadelphia; and Catalan Institution for Research and Advanced Studies (ICREA) (J.D.), Barcelona, Spain. N.G.-A. is currently affiliated with the Department of Neuroscience, Karolinska Institute, Stockholm, Sweden. Jdalmau@clinic.ub.es.
Abstract
OBJECTIVE: To report a novel autoimmune encephalitis in which the antibodies target neurexin-3α, a cell adhesion molecule involved in the development and function of synapses. METHODS: Five patients with encephalitis and antibodies with a similar pattern of brain reactivity were selected. Antigen precipitation and determination of antibody effects on cultured rat embryonic neurons were performed with reported techniques. RESULTS: Immunoprecipitation and cell-based assays identified neurexin-3α as the autoantigen of patients' antibodies. All 5 patients (median age 44 years, range 23-50; 4 female) presented with prodromal fever, headache, or gastrointestinal symptoms, followed by confusion, seizures, and decreased level of consciousness. Two developed mild orofacial dyskinesias, 3 needed respiratory support, and 4 had findings suggesting propensity to autoimmunity. CSF was abnormal in all patients (4 pleocytosis, 1 elevated immunoglobulin G [IgG] index), and brain MRI was abnormal in 1 (increased fluid-attenuated inversion recovery/T2 in temporal lobes). All received steroids, 1 IV immunoglobulin, and 1 cyclophosphamide; 3 partially recovered, 1 died of sepsis while recovering, and 1 had a rapid progression to death. At autopsy, edema but no inflammatory cells were identified. Cultures of neurons exposed during days in vitro (div) 7-17 to patients' IgG showed a decrease of neurexin-3α clusters as well as the total number of synapses. No reduction of synapses occurred in mature neurons (div 18) exposed for 48 hours to patients' IgG. Neuronal survival, dendritic morphology, and spine density were unaffected. CONCLUSION: Neurexin-3α autoantibodies associate with a severe but potentially treatable encephalitis in which the antibodies cause a decrease of neurexin-3α and alter synapse development.
OBJECTIVE: To report a novel autoimmune encephalitis in which the antibodies target neurexin-3α, a cell adhesion molecule involved in the development and function of synapses. METHODS: Five patients with encephalitis and antibodies with a similar pattern of brain reactivity were selected. Antigen precipitation and determination of antibody effects on cultured rat embryonic neurons were performed with reported techniques. RESULTS: Immunoprecipitation and cell-based assays identified neurexin-3α as the autoantigen of patients' antibodies. All 5 patients (median age 44 years, range 23-50; 4 female) presented with prodromal fever, headache, or gastrointestinal symptoms, followed by confusion, seizures, and decreased level of consciousness. Two developed mild orofacial dyskinesias, 3 needed respiratory support, and 4 had findings suggesting propensity to autoimmunity. CSF was abnormal in all patients (4 pleocytosis, 1 elevated immunoglobulin G [IgG] index), and brain MRI was abnormal in 1 (increased fluid-attenuated inversion recovery/T2 in temporal lobes). All received steroids, 1 IV immunoglobulin, and 1 cyclophosphamide; 3 partially recovered, 1 died of sepsis while recovering, and 1 had a rapid progression to death. At autopsy, edema but no inflammatory cells were identified. Cultures of neurons exposed during days in vitro (div) 7-17 to patients' IgG showed a decrease of neurexin-3α clusters as well as the total number of synapses. No reduction of synapses occurred in mature neurons (div 18) exposed for 48 hours to patients' IgG. Neuronal survival, dendritic morphology, and spine density were unaffected. CONCLUSION: Neurexin-3α autoantibodies associate with a severe but potentially treatable encephalitis in which the antibodies cause a decrease of neurexin-3α and alter synapse development.
Authors: Julie Gauthier; Tabrez J Siddiqui; Peng Huashan; Daisaku Yokomaku; Fadi F Hamdan; Nathalie Champagne; Mathieu Lapointe; Dan Spiegelman; Anne Noreau; Ronald G Lafrenière; Ferid Fathalli; Ridha Joober; Marie-Odile Krebs; Lynn E DeLisi; Laurent Mottron; Eric Fombonne; Jacques L Michaud; Pierre Drapeau; Salvatore Carbonetto; Ann Marie Craig; Guy A Rouleau Journal: Hum Genet Date: 2011-03-22 Impact factor: 4.132
Authors: Andrea K Vaags; Anath C Lionel; Daisuke Sato; McKinsey Goodenberger; Quinn P Stein; Sarah Curran; Caroline Ogilvie; Joo Wook Ahn; Irene Drmic; Lili Senman; Christina Chrysler; Ann Thompson; Carolyn Russell; Aparna Prasad; Susan Walker; Dalila Pinto; Christian R Marshall; Dimitri J Stavropoulos; Lonnie Zwaigenbaum; Bridget A Fernandez; Eric Fombonne; Patrick F Bolton; David A Collier; Jennelle C Hodge; Wendy Roberts; Peter Szatmari; Stephen W Scherer Journal: Am J Hum Genet Date: 2011-12-29 Impact factor: 11.025
Authors: Neil M Vora; Robert C Holman; Jason M Mehal; Claudia A Steiner; Jesse Blanton; James Sejvar Journal: Neurology Date: 2014-01-02 Impact factor: 9.910
Authors: Josep Dalmau; Amy J Gleichman; Ethan G Hughes; Jeffrey E Rossi; Xiaoyu Peng; Meizan Lai; Scott K Dessain; Myrna R Rosenfeld; Rita Balice-Gordon; David R Lynch Journal: Lancet Neurol Date: 2008-10-11 Impact factor: 44.182
Authors: Xiaoyu Peng; Ethan G Hughes; Emilia H Moscato; Thomas D Parsons; Josep Dalmau; Rita J Balice-Gordon Journal: Ann Neurol Date: 2015-01-29 Impact factor: 10.422